Skip to main content
Top
Published in: Clinical Rheumatology 2/2010

01-02-2010 | Original Article

Musculoskeletal manifestations in patients with malignant disease

Authors: Tamer A. Gheita, Yasser Ezzat, Safaa Sayed, Ghada El-Mardenly, Waleed Hammam

Published in: Clinical Rheumatology | Issue 2/2010

Login to get access

Abstract

To detect and describe the incidence of musculoskeletal manifestations in different malignant diseases as well as their relation to the treatment received whether by chemotherapy or radiation therapy. Sixty patients with different malignant diseases were included in this study, 45 with solid tumors and 15 patients with hematological malignancy. The mean age was 46.55 ± 11.04 years and the mean disease duration was 2 ± 0.75 years. The patients were fully examined for any rheumatologic involvement, laboratory investigations were performed as well as dual energy X-ray absorptiometry study for bone densitometry. Treatment strategies were assessed including the chemotherapeutics, radiation therapy, and/or surgery. Myalgias and arthralgias were the most frequent followed by flexor tenosynovitis, frozen shoulder, and fibromyalgia syndrome. Hypertrophic osteoarthropathy was seen in five patients, cutaneous vasculitis in two patients as well as arthritis. Osteonecrosis was present in one of the lunate carpal bones of a patient with non-Hodgkin’s lymphoma (1.67%) and receiving high dose steroids. Rheumatoid factor was positive in four patients, three of which had hepatitis C virus positivity and cryoglobulins. Anti-neutrophil cytoplasmic antibody was negative in all the studied patients. The bone mineral density was significantly reduced in the patients with malignancy compared to the control. Mild to moderate osteoporosis was present, being more evident in the spine and forearm. The bone loss was higher in those with solid tumors and even more obvious in those receiving aromatase inhibitors. Musculoskeletal manifestations occurring during malignancies and following the treatment represent a significant percentage of symptoms and signs which may raise a clue to differential diagnosis.
Literature
1.
go back to reference Naschitz JE, Rosner I (2008) Musculoskeletal syndromes associated with malignancy (excluding hypertrophic osteoarthropathy). Curr Opin Rheumatol 20:100CrossRefPubMed Naschitz JE, Rosner I (2008) Musculoskeletal syndromes associated with malignancy (excluding hypertrophic osteoarthropathy). Curr Opin Rheumatol 20:100CrossRefPubMed
2.
go back to reference Carsons S (1997) The association of malignancy with rheumatic and connective tissue diseases. Semin Oncol 24:360PubMed Carsons S (1997) The association of malignancy with rheumatic and connective tissue diseases. Semin Oncol 24:360PubMed
3.
go back to reference Naschitz JE, Rosner I, Rozenbaum M, Zuckerman E, Yeshurun D (1999) Rheumatic syndromes: clues to occult neoplasia. Semin Arthritis Rheum 29:43CrossRefPubMed Naschitz JE, Rosner I, Rozenbaum M, Zuckerman E, Yeshurun D (1999) Rheumatic syndromes: clues to occult neoplasia. Semin Arthritis Rheum 29:43CrossRefPubMed
4.
go back to reference Naschitz JE, Yeshurun D, Rosner I (2954) Rheumatic manifestations of occult cancer. Cancer 1995:75 Naschitz JE, Yeshurun D, Rosner I (2954) Rheumatic manifestations of occult cancer. Cancer 1995:75
5.
go back to reference Morel J, Deschamps V, Toussirot E, Pertuiset E, Sordet C, Kieffer P, Berthelot JM, Champagne H, Mariette X, Combe B (2008) Characterisitics and survival of 26 patients with paraneoplastic arthritis. Ann Rheum Dis 67:244CrossRefPubMed Morel J, Deschamps V, Toussirot E, Pertuiset E, Sordet C, Kieffer P, Berthelot JM, Champagne H, Mariette X, Combe B (2008) Characterisitics and survival of 26 patients with paraneoplastic arthritis. Ann Rheum Dis 67:244CrossRefPubMed
6.
go back to reference Mariette X, de Roquancourt A, d’Agay MF, Gisselbrecht C, Clauvel JP, Oksenhendler E (1988) Monoarthritis revealing non-Hodgkin’s T-cell lymphoma of the synovium. Arthritis Rheum 31:571CrossRefPubMed Mariette X, de Roquancourt A, d’Agay MF, Gisselbrecht C, Clauvel JP, Oksenhendler E (1988) Monoarthritis revealing non-Hodgkin’s T-cell lymphoma of the synovium. Arthritis Rheum 31:571CrossRefPubMed
7.
go back to reference Gridley G, McLaughlin JK, Ekbom A, Klareskog L, Adami HO, Hacker DG, Hoover R, Fraumeni JF Jr (1993) Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 85:307CrossRefPubMed Gridley G, McLaughlin JK, Ekbom A, Klareskog L, Adami HO, Hacker DG, Hoover R, Fraumeni JF Jr (1993) Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 85:307CrossRefPubMed
8.
go back to reference Savin H, Zimmermann B 3rd, Aaron RK, Libbey NP, Khorsand J, Alper JC, Lally EV (1991) Seronegative symmetric polyarthritis in Sezary syndrome. J Rheumatol 18:464PubMed Savin H, Zimmermann B 3rd, Aaron RK, Libbey NP, Khorsand J, Alper JC, Lally EV (1991) Seronegative symmetric polyarthritis in Sezary syndrome. J Rheumatol 18:464PubMed
9.
go back to reference Ehrenfeld M, Gur H, Shonenfeld Y (1999) Rheumatologic features of hematologic disease. Curr Opin Rheumatol 11:62CrossRefPubMed Ehrenfeld M, Gur H, Shonenfeld Y (1999) Rheumatologic features of hematologic disease. Curr Opin Rheumatol 11:62CrossRefPubMed
10.
go back to reference Kransdorf MJ (1995) Malignant soft-tissue tumors in a large referral population: distribution of diagnoses by age, sex, and location. AJR Am J Roentgenol 164:129PubMed Kransdorf MJ (1995) Malignant soft-tissue tumors in a large referral population: distribution of diagnoses by age, sex, and location. AJR Am J Roentgenol 164:129PubMed
11.
go back to reference Loughran TP Jr (1993) Clonal diseases of large granular lymphocytes. Blood 82:1PubMed Loughran TP Jr (1993) Clonal diseases of large granular lymphocytes. Blood 82:1PubMed
12.
go back to reference Avina-Zubieta JA, Galindo-Rodriguez G, Lavalle C (1998) Rheumatic manifestations of hematologic disorders. Curr Opin Rheumatol 10:86CrossRefPubMed Avina-Zubieta JA, Galindo-Rodriguez G, Lavalle C (1998) Rheumatic manifestations of hematologic disorders. Curr Opin Rheumatol 10:86CrossRefPubMed
13.
go back to reference Rennie JA, Auchterlonie IA (1991) Rheumatological manifestations of the leukaemias and graft versus host disease. Baillieres Clin Rheumatol 5:231CrossRefPubMed Rennie JA, Auchterlonie IA (1991) Rheumatological manifestations of the leukaemias and graft versus host disease. Baillieres Clin Rheumatol 5:231CrossRefPubMed
15.
go back to reference Loprinzi CL, Duffy J, Ingle JN (1993) Postchemotherapy rheumatism. J Clin Oncol 11:768PubMed Loprinzi CL, Duffy J, Ingle JN (1993) Postchemotherapy rheumatism. J Clin Oncol 11:768PubMed
16.
go back to reference Kim MJ, Ye YM, Park HS, Suh CH (2006) Chemotherapy-related arthropathy. J Rheumatol 33:1364PubMed Kim MJ, Ye YM, Park HS, Suh CH (2006) Chemotherapy-related arthropathy. J Rheumatol 33:1364PubMed
17.
go back to reference Hutchins LF, Green SJ, Ravdin PM, Lew D, Martino S, Abeloff M, Lyss AP, Allred C, Rivkin SE, Osborne CK (2005) Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102. J Clin Oncol 23(33):8313–8321CrossRefPubMed Hutchins LF, Green SJ, Ravdin PM, Lew D, Martino S, Abeloff M, Lyss AP, Allred C, Rivkin SE, Osborne CK (2005) Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102. J Clin Oncol 23(33):8313–8321CrossRefPubMed
18.
go back to reference Sestak I, Cuzick J, Sapunar F, Eastell R, Forbes JF, Bianco AR, Buzdar AU, ATAC Trialists’ Group (2008) Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis. Lancet Oncol 9(9):866–872 Epub 2008 Aug 12CrossRefPubMed Sestak I, Cuzick J, Sapunar F, Eastell R, Forbes JF, Bianco AR, Buzdar AU, ATAC Trialists’ Group (2008) Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis. Lancet Oncol 9(9):866–872 Epub 2008 Aug 12CrossRefPubMed
19.
go back to reference Boccardo F, Rubagotti A, Puntoni M, Guglielmini P, Amoroso D, Fini A, Paladini G, Mesiti M, Romeo D, Rinaldini M, Scali S, Porpiglia M, Benedetto C, Restuccia N, Buzzi F, Franchi R, Massidda B, Distante V, Amadori D, Sismondi P (2005) Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol 23(22):5138–5147 Epub 2005 Jul 11CrossRefPubMed Boccardo F, Rubagotti A, Puntoni M, Guglielmini P, Amoroso D, Fini A, Paladini G, Mesiti M, Romeo D, Rinaldini M, Scali S, Porpiglia M, Benedetto C, Restuccia N, Buzzi F, Franchi R, Massidda B, Distante V, Amadori D, Sismondi P (2005) Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol 23(22):5138–5147 Epub 2005 Jul 11CrossRefPubMed
20.
go back to reference Nabholtz JA (2008) Long-term safety of aromatase inhibitors in the treatment of breast cancer. Ther Clin Risk Manag 4(1):189–204PubMed Nabholtz JA (2008) Long-term safety of aromatase inhibitors in the treatment of breast cancer. Ther Clin Risk Manag 4(1):189–204PubMed
21.
go back to reference Perez EA, Josse RG, Pritchard KI, Ingle JN, Martino S, Findlay BP, Shenkier TN, Tozer RG, Palmer MJ, Shepherd LE, Liu S, Tu D, Goss PE (2006) Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol 24(22):3629–3635 Epub 2006 Jul 5CrossRefPubMed Perez EA, Josse RG, Pritchard KI, Ingle JN, Martino S, Findlay BP, Shenkier TN, Tozer RG, Palmer MJ, Shepherd LE, Liu S, Tu D, Goss PE (2006) Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol 24(22):3629–3635 Epub 2006 Jul 5CrossRefPubMed
22.
go back to reference Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS, ATAC Trialists’ Group (2005) Results of the ATAC (Arimidex, Tamoxifen, alone or in combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 365(9453):60–62CrossRefPubMed Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS, ATAC Trialists’ Group (2005) Results of the ATAC (Arimidex, Tamoxifen, alone or in combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 365(9453):60–62CrossRefPubMed
23.
go back to reference Lønning PE, Geisler J, Krag LE, Erikstein B, Bremnes Y, Hagen AI, Schlichting E, Lien EA, Ofjord ES, Paolini J, Polli A, Massimini G (2005) Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol 23(22):5126–5137 Epub 2005 Jun 27CrossRefPubMed Lønning PE, Geisler J, Krag LE, Erikstein B, Bremnes Y, Hagen AI, Schlichting E, Lien EA, Ofjord ES, Paolini J, Polli A, Massimini G (2005) Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol 23(22):5126–5137 Epub 2005 Jun 27CrossRefPubMed
24.
go back to reference Chien AJ, Goss PE (2006) Aromatase inhibitors and bone health in women with breast cancer. J Clin Oncol 24(33):5305–5312CrossRefPubMed Chien AJ, Goss PE (2006) Aromatase inhibitors and bone health in women with breast cancer. J Clin Oncol 24(33):5305–5312CrossRefPubMed
25.
go back to reference Crew KD, Greenlee H, Capodice J, Raptis G, Brafman L, Fuentes D, Sierra A, Hershman DL (2007) Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol 25(25):3877–3883CrossRefPubMed Crew KD, Greenlee H, Capodice J, Raptis G, Brafman L, Fuentes D, Sierra A, Hershman DL (2007) Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol 25(25):3877–3883CrossRefPubMed
26.
go back to reference Presant CA, Bosserman L, Young T, Vakil M, Horns R, Upadhyaya G, Ebrahimi B, Yeon C, Howard F (2007) Aromatase inhibitor-associated arthralgia and/or bone pain: frequency and characterization in non-clinical trial patients. Clin Breast Cancer 7(10):775–778CrossRefPubMed Presant CA, Bosserman L, Young T, Vakil M, Horns R, Upadhyaya G, Ebrahimi B, Yeon C, Howard F (2007) Aromatase inhibitor-associated arthralgia and/or bone pain: frequency and characterization in non-clinical trial patients. Clin Breast Cancer 7(10):775–778CrossRefPubMed
27.
go back to reference Henry NL, Giles JT, Ang D, Mohan M, Dadabhoy D, Robarge J, Hayden J, Lemler S, Shahverdi K, Powers P, Li L, Flockhart D, Stearns V, Hayes DF, Storniolo AM, Clauw DJ (2008) Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Res Treat 111(2):365–372CrossRefPubMed Henry NL, Giles JT, Ang D, Mohan M, Dadabhoy D, Robarge J, Hayden J, Lemler S, Shahverdi K, Powers P, Li L, Flockhart D, Stearns V, Hayes DF, Storniolo AM, Clauw DJ (2008) Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Res Treat 111(2):365–372CrossRefPubMed
28.
go back to reference Morales L, Neven P, Timmerman D, Wildiers H, Konstantinovic ML, Christiaens MR, Tan PN, Paridaens R (2009) Prospective assessment of the endometrium in postmenopausal breast cancer patients treated with fulvestrant. Breast Cancer Res Treat 117(1):77–81CrossRefPubMed Morales L, Neven P, Timmerman D, Wildiers H, Konstantinovic ML, Christiaens MR, Tan PN, Paridaens R (2009) Prospective assessment of the endometrium in postmenopausal breast cancer patients treated with fulvestrant. Breast Cancer Res Treat 117(1):77–81CrossRefPubMed
29.
go back to reference Brufsky A, Harker WG, Beck JT, Carroll R, Tan-Chiu E, Seidler C, Hohneker J, Lacerna L, Petrone S, Perez EA (2007) Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 25(7):829–836 Epub 2006 Dec 11CrossRefPubMed Brufsky A, Harker WG, Beck JT, Carroll R, Tan-Chiu E, Seidler C, Hohneker J, Lacerna L, Petrone S, Perez EA (2007) Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 25(7):829–836 Epub 2006 Dec 11CrossRefPubMed
30.
go back to reference Kiltz U, Brandt J, Zochling J, Braun J (2007) Rheumatic manifestations of lymphoproliferative disorders. Clin Exp Rheumatol 25(1):35–39PubMed Kiltz U, Brandt J, Zochling J, Braun J (2007) Rheumatic manifestations of lymphoproliferative disorders. Clin Exp Rheumatol 25(1):35–39PubMed
31.
go back to reference Fam AG (2000) Paraneoplastic rheumatic syndromes. Bailliere’s Best Pract Res Clin Rheumatol 14(3):515–533CrossRef Fam AG (2000) Paraneoplastic rheumatic syndromes. Bailliere’s Best Pract Res Clin Rheumatol 14(3):515–533CrossRef
32.
go back to reference Jesus G, Barcelos A, Neves C, Crespo J (2006) Rheumatic manifestations and neoplasms. Acta Reumatol Port 31(4):305–321PubMed Jesus G, Barcelos A, Neves C, Crespo J (2006) Rheumatic manifestations and neoplasms. Acta Reumatol Port 31(4):305–321PubMed
33.
go back to reference Dabrowska-Zimoń A, Brzosko M (2006) A review of paraneoplastic rheumatic syndromes. Ann Acad Med Stetin 52(Suppl 2):17–22PubMed Dabrowska-Zimoń A, Brzosko M (2006) A review of paraneoplastic rheumatic syndromes. Ann Acad Med Stetin 52(Suppl 2):17–22PubMed
34.
go back to reference Brooks PM (1992) Rheumatic manifestations of neoplasia. Curr Opin Rheumatol 4(1):90–93PubMed Brooks PM (1992) Rheumatic manifestations of neoplasia. Curr Opin Rheumatol 4(1):90–93PubMed
35.
go back to reference Oztürkcan S, Ozel F, Doğan S, Seyfikli Z, Hatipoğlu A (2003) The skin manifestations in patients with lung cancers. Tuberk Toraks 51(1):23–26PubMed Oztürkcan S, Ozel F, Doğan S, Seyfikli Z, Hatipoğlu A (2003) The skin manifestations in patients with lung cancers. Tuberk Toraks 51(1):23–26PubMed
36.
go back to reference Kurzrock R, Cohen PR (1995) Cutaneous paraneoplastic syndromes in solid tumors. Am J Med 99(6):662–671CrossRefPubMed Kurzrock R, Cohen PR (1995) Cutaneous paraneoplastic syndromes in solid tumors. Am J Med 99(6):662–671CrossRefPubMed
37.
go back to reference Raffayova H, Schultz P, Malis F (2000) Secondary hypertrophic osteoarthropathy in a patient with pulmonary carcinoma. Bratisl Lek Listy 101(4):219–222PubMed Raffayova H, Schultz P, Malis F (2000) Secondary hypertrophic osteoarthropathy in a patient with pulmonary carcinoma. Bratisl Lek Listy 101(4):219–222PubMed
38.
go back to reference Abe Y, Kurita S, Ohkubo Y, Usui H, Hashizume T, Nakamura M, Ueyama Y, Fujino T (2002) A case of pulmonary adenocarcinoma associated with hypertrophic osteoarthropathy due to vascular endothelial growth factor. Anticancer Res 22(6B):3485–3488PubMed Abe Y, Kurita S, Ohkubo Y, Usui H, Hashizume T, Nakamura M, Ueyama Y, Fujino T (2002) A case of pulmonary adenocarcinoma associated with hypertrophic osteoarthropathy due to vascular endothelial growth factor. Anticancer Res 22(6B):3485–3488PubMed
39.
go back to reference Fridlington J, Weaver J, Kelly B, Kelly E (2007) Secondary hypertrophic osteoarthropathy associated with solitary fibrous tumor of the lung. J Am Acad Dermatol 57(5 Suppl):S106–S110CrossRefPubMed Fridlington J, Weaver J, Kelly B, Kelly E (2007) Secondary hypertrophic osteoarthropathy associated with solitary fibrous tumor of the lung. J Am Acad Dermatol 57(5 Suppl):S106–S110CrossRefPubMed
40.
go back to reference Massarotti M, Ciocia G, Ceriani R, Chiti A, Marasini B (2008) Metastatic gastric cancer presenting with shoulder-hand syndrome: a case report. J Med Case Reports 2:240CrossRefPubMed Massarotti M, Ciocia G, Ceriani R, Chiti A, Marasini B (2008) Metastatic gastric cancer presenting with shoulder-hand syndrome: a case report. J Med Case Reports 2:240CrossRefPubMed
41.
go back to reference Cheville AL, Tchou J (2007) Barriers to rehabilitation following surgery for primary breast cancer. J Surg Oncol 95(5):409–418CrossRefPubMed Cheville AL, Tchou J (2007) Barriers to rehabilitation following surgery for primary breast cancer. J Surg Oncol 95(5):409–418CrossRefPubMed
42.
go back to reference Sheehy C, Ryan JG, Kelly M, Barry M (2007) Palmar fasciitis and polyarthritis syndrome associated with non-small-cell lung carcinoma. Clin Rheumatol 26(11):1951–1953 Epub 2007 Feb 20CrossRefPubMed Sheehy C, Ryan JG, Kelly M, Barry M (2007) Palmar fasciitis and polyarthritis syndrome associated with non-small-cell lung carcinoma. Clin Rheumatol 26(11):1951–1953 Epub 2007 Feb 20CrossRefPubMed
43.
go back to reference Eyigor S, Karapolat H, Korkmaz OK, Eyigor C, Durmaz B, Uslu R, Uyar M (2009) The frequency of fibromyalgia syndrome and quality of life in hospitalized cancer patients. Eur J Cancer Care (Engl) 18(2):195–201CrossRef Eyigor S, Karapolat H, Korkmaz OK, Eyigor C, Durmaz B, Uslu R, Uyar M (2009) The frequency of fibromyalgia syndrome and quality of life in hospitalized cancer patients. Eur J Cancer Care (Engl) 18(2):195–201CrossRef
44.
go back to reference Fain O, Hamidou M, Cacoub P, Godeau B, Wechsler B, Pariès J, Stirnemann J, Morin A, Gatfosse M, Hanslik T, Belmatoug N, Blètry O, Cevallos R, Delevaux I, Fisher E, Hayem G, Kaplan G, Le Hello C, Mouthon L, Larroche C, Lemaire V, Piette A, Piette J, Ponge T, Puechal X, Rossert J, Sarrot R, Sicard D, Ziza J, Kahn M, Guillevin L (2007) Vasculitides associated malignancies: analysis of sixty patients. Arthritis Rheum 57:1473CrossRefPubMed Fain O, Hamidou M, Cacoub P, Godeau B, Wechsler B, Pariès J, Stirnemann J, Morin A, Gatfosse M, Hanslik T, Belmatoug N, Blètry O, Cevallos R, Delevaux I, Fisher E, Hayem G, Kaplan G, Le Hello C, Mouthon L, Larroche C, Lemaire V, Piette A, Piette J, Ponge T, Puechal X, Rossert J, Sarrot R, Sicard D, Ziza J, Kahn M, Guillevin L (2007) Vasculitides associated malignancies: analysis of sixty patients. Arthritis Rheum 57:1473CrossRefPubMed
45.
go back to reference Harper PG, Trask C, Souhami RL (1984) Avascular necrosis of bone caused by combination chemotherapy without corticosteroids. Br Med J (Clin Res Ed) 288(6413):267–268CrossRef Harper PG, Trask C, Souhami RL (1984) Avascular necrosis of bone caused by combination chemotherapy without corticosteroids. Br Med J (Clin Res Ed) 288(6413):267–268CrossRef
46.
go back to reference Budoff JE (2006) Concomitant Kienböck’s and Preiser’s diseases: a case report. J Hand Surg Am 31(7):1149–1153CrossRefPubMed Budoff JE (2006) Concomitant Kienböck’s and Preiser’s diseases: a case report. J Hand Surg Am 31(7):1149–1153CrossRefPubMed
47.
go back to reference Kato H, Ogino T, Minami A (1991) Steroid-induced avascular necrosis of the capitate. A case report. Handchir Mikrochir Plast Chir. 23(1):15–17PubMed Kato H, Ogino T, Minami A (1991) Steroid-induced avascular necrosis of the capitate. A case report. Handchir Mikrochir Plast Chir. 23(1):15–17PubMed
48.
go back to reference Culp RW, Schaffer JL, Osterman AL, Bora FW Jr (1989) Kienböck’s disease in a patient with Crohn’s enteritis treated with corticosteroids. J Hand Surg Am 14(2 Pt 1):294–296CrossRefPubMed Culp RW, Schaffer JL, Osterman AL, Bora FW Jr (1989) Kienböck’s disease in a patient with Crohn’s enteritis treated with corticosteroids. J Hand Surg Am 14(2 Pt 1):294–296CrossRefPubMed
49.
go back to reference Winters L, Habin K, Gallagher J (2007) Aromatase inhibitors and musculoskeletal pain in patients with breast cancer. Clin J Oncol Nurs 11(3):433–439CrossRefPubMed Winters L, Habin K, Gallagher J (2007) Aromatase inhibitors and musculoskeletal pain in patients with breast cancer. Clin J Oncol Nurs 11(3):433–439CrossRefPubMed
50.
go back to reference Nemitz N, Kurmann PT, Van Linthoudt D (2008) Intensification of a diffuse chronic pain syndrome by the introduction of an aromatase inhibitor. Praxis (Bern 1994) 97(3):137–141CrossRef Nemitz N, Kurmann PT, Van Linthoudt D (2008) Intensification of a diffuse chronic pain syndrome by the introduction of an aromatase inhibitor. Praxis (Bern 1994) 97(3):137–141CrossRef
51.
go back to reference Coleman RE, Bolten WW, Lansdown M, Dale S, Jackisch C, Merkel D, Maass N, Hadji P (2008) Aromatase inhibitor-induced arthralgia: clinical experience and treatment recommendations. Cancer Treat Rev 34(3):275–282 Epub 2007 Dec 21CrossRefPubMed Coleman RE, Bolten WW, Lansdown M, Dale S, Jackisch C, Merkel D, Maass N, Hadji P (2008) Aromatase inhibitor-induced arthralgia: clinical experience and treatment recommendations. Cancer Treat Rev 34(3):275–282 Epub 2007 Dec 21CrossRefPubMed
52.
go back to reference Burstein HJ (2007) Aromatase inhibitor-associated arthralgia syndrome. Breast 16(3):223–234 Epub 2007 Mar 21CrossRefPubMed Burstein HJ (2007) Aromatase inhibitor-associated arthralgia syndrome. Breast 16(3):223–234 Epub 2007 Mar 21CrossRefPubMed
53.
go back to reference Saadoun D, Landau DA, Calabrese LH, Cacoub PP (2007) Hepatitis C-associated mixed cryoglobulinaemia: a crossroad between autoimmunity and lymphoproliferation. Rheumatology (Oxford) 46(8):1234–1242 Epub 2007 Jun 12CrossRef Saadoun D, Landau DA, Calabrese LH, Cacoub PP (2007) Hepatitis C-associated mixed cryoglobulinaemia: a crossroad between autoimmunity and lymphoproliferation. Rheumatology (Oxford) 46(8):1234–1242 Epub 2007 Jun 12CrossRef
54.
go back to reference Hamidou MA, Boumalassa A, Larroche C, El Kouri D, Blétry O, Grolleau JY (2001) Systemic medium-sized vessel vasculitis associated with chronic myelomonocytic leukemia. Semin Arthritis Rheum 31(2):119–126CrossRefPubMed Hamidou MA, Boumalassa A, Larroche C, El Kouri D, Blétry O, Grolleau JY (2001) Systemic medium-sized vessel vasculitis associated with chronic myelomonocytic leukemia. Semin Arthritis Rheum 31(2):119–126CrossRefPubMed
55.
go back to reference Simon Z, Tarr T, Tóth L, Szucs G, Illés A (2008) Cutaneous vasculitis as an initiating paraneoplastic symptom in Hodgkin lymphoma. Rheumatol Int 28(7):719–723 Epub 2007 Dec 19CrossRefPubMed Simon Z, Tarr T, Tóth L, Szucs G, Illés A (2008) Cutaneous vasculitis as an initiating paraneoplastic symptom in Hodgkin lymphoma. Rheumatol Int 28(7):719–723 Epub 2007 Dec 19CrossRefPubMed
56.
go back to reference Sato N, Tsubochi H, Kishimoto K, Imai T, Kaimori M (2007) Anti-neutrophil cytoplasmic anti body (ANCA)-negative limited form of Wegener’s granulomatosis: report of a case. Kyobu Geka 60(7):591–594PubMed Sato N, Tsubochi H, Kishimoto K, Imai T, Kaimori M (2007) Anti-neutrophil cytoplasmic anti body (ANCA)-negative limited form of Wegener’s granulomatosis: report of a case. Kyobu Geka 60(7):591–594PubMed
57.
go back to reference Hamidou MA, Derenne S, Audrain MA, Berthelot JM, Boumalassa A, Grolleau JY (2000) Prevalence of rheumatic manifestations and antineutrophil cytoplasmic antibodies in haematological malignancies. A prospective study. Rheumatology (Oxford) 39(4):417–420CrossRef Hamidou MA, Derenne S, Audrain MA, Berthelot JM, Boumalassa A, Grolleau JY (2000) Prevalence of rheumatic manifestations and antineutrophil cytoplasmic antibodies in haematological malignancies. A prospective study. Rheumatology (Oxford) 39(4):417–420CrossRef
58.
go back to reference Wong M, Grossman J, Hahn BH, La Cava A (2008) Cutaneous vasculitis in breast cancer treated with chemotherapy. Clin Immunol 129(1):3–9 Epub 2008 Jul 21CrossRefPubMed Wong M, Grossman J, Hahn BH, La Cava A (2008) Cutaneous vasculitis in breast cancer treated with chemotherapy. Clin Immunol 129(1):3–9 Epub 2008 Jul 21CrossRefPubMed
59.
go back to reference Muslimani AA, Spiro TP, Chaudhry AA, Taylor HC, Do IJ, Daw HA (2009) Aromatase inhibitor-related musculoskeletal symptoms: is preventing osteoporosis the key to eliminating these symptoms? Clin Breast Cancer 9(1):34–38CrossRefPubMed Muslimani AA, Spiro TP, Chaudhry AA, Taylor HC, Do IJ, Daw HA (2009) Aromatase inhibitor-related musculoskeletal symptoms: is preventing osteoporosis the key to eliminating these symptoms? Clin Breast Cancer 9(1):34–38CrossRefPubMed
Metadata
Title
Musculoskeletal manifestations in patients with malignant disease
Authors
Tamer A. Gheita
Yasser Ezzat
Safaa Sayed
Ghada El-Mardenly
Waleed Hammam
Publication date
01-02-2010
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 2/2010
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-009-1310-0

Other articles of this Issue 2/2010

Clinical Rheumatology 2/2010 Go to the issue